All In Biotech

Drug Trial Radar · NCT05123755

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Dec 20, 2021

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Vasomune Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

Conditions

  • Acute Respiratory Distress Syndrome
  • Viral or Bacterial Infections
  • Pneumonia
  • Pneumonia, Viral
  • Respiratory Infection
  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

  • AV-001 InjectionDrug

    AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

  • AV-001 Placebo InjectionDrug

    D-PBS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of multiple doses of IV administrations of AV-001 Injection compared with AV-001 placebo Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.Time frame: Up to Day 60

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Denver Health Medical Center

    Denver, Colorado

  • Northwestern University Medical Center

    Chicago, Illinois

  • MedStar Health Research Institute, Inc.

    Hyattsville, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • The Ohio State University

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.